Targeted agents directed against VEGF-R like axitinib (AG-013736) or against BRAF and VEGF-R like sorafenib (Nexavar®) have been tested in phase II trials including patients with anaplastic thyroid carcinoma [20,21]. Here, KDR is linked to thyroid gland undifferentiated (anaplastic) carcinoma.